Alzheimer's Dementia: Blood AD biomarker concentration is related to pathology and clinical diagnosis

Alzheimer's disease (AD) is the main cause of dementia.

In 1984, the National Institute of Neural and Communication Diseases and Stroke -Alzheimer’s and Related Diseases Association (NINCDS-ADRDA) used the diagnostic criteria for AD to be divided into three diagnostic levels: clear AD (neuropathological diagnosis), extreme Probable AD (clinical diagnosis), possible AD (clinical diagnosis with comorbidities).

Stroke diagnosis

Compared with postmortem diagnosis, the sensitivity and specificity of clinical criteria for probable AD are 81% and 70%, respectively.

In 2011, the updated standards recognized that the pathological process had begun before clinical symptoms appeared.
The use of magnetic resonance imaging (MRI), positron emission tomography (PET) imaging, and cerebrospinal fluid (CSF) testing is more systematically incorporated into the diagnosis.

Clinically, it is easier to include biomarkers in the diagnosis of AD than to include biomarkers in observational studies.
Due to limitations in obtaining radiopharmaceuticals and performing lumbar punctures, the widespread use of PET and CSF biomarkers is difficult.

The recent development of AD blood group biomarkers may overcome these problems and provide an opportunity to improve the diagnostic accuracy of observational studies.

The recent development of AD blood group biomarkers may overcome these problems and provide an opportunity to improve the diagnostic accuracy of observational studies.
The recent development of AD blood group biomarkers may overcome these problems and provide an opportunity to improve the diagnostic accuracy of observational studies.

Adam M.

Brickman and others of Columbia University in the United States, based on the Washington Heights-Inwood Columbia Aging Project (WHICAP) cohort, which is a multi-ethnic community study of aging and dementia.

They found that the plasma biomarker concentration of phosphorylated tau, especially p-tau217, was closely related to AD confirmed by autopsy.

Including higher concentrations of p-tau217 and NfL, the classification accuracy is quite good.

P-tau biomarkers are also associated with amyloid pathology on PET, and are more relevant than other plasma biomarkers, including Aβ42/Aβ40.

The lower Aβ42/Aβ40 ratio and higher p-tau217 or p-tau181 concentration are related to the increased risk of subsequent AD diagnosis.

The lower Aβ42/Aβ40 ratio and higher p-tau217 or p-tau181 concentration are related to the increased risk of subsequent AD diagnosis.
The lower Aβ42/Aβ40 ratio and higher p-tau217 or p-tau181 concentration are related to the increased risk of subsequent AD diagnosis.

 

The important significance of this study is that it is found that the blood AD biomarker concentration is related to pathology and clinical diagnosis, and can predict the future development of clinical AD, and provides evidence that can be included in multi-ethnic and community studies.

It was found that the AD biomarker concentration in blood is related to pathology and clinical diagnosis, and can predict the future development of clinical AD, providing evidence that can be included in multi-ethnic and community studies.
It was found that the AD biomarker concentration in blood is related to pathology and clinical diagnosis, and can predict the future development of clinical AD, providing evidence that can be included in multi-ethnic and community studies.

Original Source: onlinelibrary.

wiley.
com/doi/10.

onlinelibrary.
wiley.
com/doi/10.
1002/alz.
12301" target="_blank" rel="noopener">Brickman, AM, Manly, JJ, Honig, L.
, Sanchez, D.
, Reyes-Dumeyer, D.
, Lantigua, RA, .
.
.
& Mayeux, R.
(2020).
Plasma P-tau 181, P-tau 217 and Other Blood-Based Alzheimer's Disease Biomarkers in a Multi-Ethnic, Community Study.
Alzheimer's & Dementia leave a message here